NCT07035405View on ClinicalTrials.gov

Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

7,500

Participants

Timeline

Start Date

July 4, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Stroke
Interventions
DRUG

Colchicine 0.5 mg

Oral colchicine will be initiated with a dose of 0.5 mg per day.

DRUG

Placebo colchicine

Oral placebo colchicine will be initiated with a dose of 0.5 mg per day.

All Listed Sponsors
collaborator

Shenzhen Medical Academy of Research and Translation

UNKNOWN

lead

Beijing Tiantan Hospital

OTHER